2.32
Tuhura Biosciences Inc (HURA) 最新ニュース
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
HURA Stock Price, Quote & Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
Citizens initiates TuHURA Biosciences stock with outperform rating By Investing.com - Investing.com South Africa
Citizens initiates TuHURA Biosciences stock with outperform rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Nigeria
Tuhura Biosciences secures $50 million credit facility, extends cash runway to 2028 - MSN
TuHURA Biosciences secures $50M credit facility from affiliate By Investing.com - Investing.com India
HURA (TuHURA Biosciences Inc.) posts 28.2 percent negative Q4 2025 EPS surprise, with shares falling 1.35 percent today.Community Risk Signals - UBND thành phố Hải Phòng
TuHURA Biosciences secures $50M credit facility from affiliate - Investing.com
TuHURA Biosciences Secures $50 Million Credit Facility - TipRanks
TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty - Stock Titan
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
TuHURA Biosciences Advances Cancer Drug Trials Following 2025 Results - HarianBasis.co
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money? - Insider Monkey
TuHURA Biosciences (HURA) Stock Abandons TuHURA Biosciences (HURA) Stock (Risk Aversion) 2026-04-16Momentum Signals - UBND thành phố Hải Phòng
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw Initiates TuHURA Biosciences(HURA.US) With Buy Rating, Announces Target Price $7 - Moomoo
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen - MarketBeat
Equities Analysts Set Expectations for HURA FY2026 Earnings - MarketBeat
Brookline Capital Markets Comments on HURA Q1 Earnings - MarketBeat
Downgrade Watch: What is the target price for TuHURA Biosciences Inc stockWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst - MarketBeat
HURA.O PE Ratio & Valuation, Is HURA.O Overvalued - Intellectia AI
Aug Rallies: Does TuHURA Biosciences Inc. align with a passive investing strategyTrade Volume Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Hedge Fund Moves: Is TuHURA Biosciences Inc a strong candidate for buy and hold - baoquankhu1.vn
HURA: 2025 Financial Results - Yahoo Finance
TuHURA Biosciences Acquires Kineta in $16.6M Merger and Closes $12.6M Private Placement – Key Details and Financial Impact - Minichart
TuHURA Biosciences approves executive bonuses and salary increases By Investing.com - Investing.com India
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments - TipRanks
TuHURA Biosciences approves executive bonuses and salary increases - Investing.com
Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. - TradingView
TuHURA (NASDAQ: HURA) $50M ATM equity facility via H.C. Wainwright - Stock Titan
TuHURA awards bonuses to James Bianco and Dan Dearborn, adjusts salaries - TradingView
Kineta deal and $11.5M raise shape TuHURA Biosciences (NASDAQ: HURA) 2025 results - Stock Titan
TuHURA Appoints New SVP of Clinical Operations - Intellectia AI
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - Sahm
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP - Investing.com
Cancer drug developer hires 20-year veteran to run clinical trials - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
HURA SEC FilingsTuHURA Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Risk: What dividend growth rate does TuHURA Biosciences Inc offer2026 Closing Moves & Detailed Earnings Play Strategies - baoquankhu1.vn
Is TuHURA Biosciences (HURA) Stock a Safe Investment | Price at $1.46, Up 3.19%Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
EPS Watch: Does TuHURA Biosciences Inc stock reflect fundamentals2026 Technical Patterns & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
大文字化:
|
ボリューム (24 時間):